JP2011528897A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528897A5
JP2011528897A5 JP2011519187A JP2011519187A JP2011528897A5 JP 2011528897 A5 JP2011528897 A5 JP 2011528897A5 JP 2011519187 A JP2011519187 A JP 2011519187A JP 2011519187 A JP2011519187 A JP 2011519187A JP 2011528897 A5 JP2011528897 A5 JP 2011528897A5
Authority
JP
Japan
Prior art keywords
tuberculosis
prevention
treatment
protein sequence
rv1753c protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011519187A
Other languages
English (en)
Japanese (ja)
Other versions
JP5824360B2 (ja
JP2011528897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/059586 external-priority patent/WO2010010180A1/en
Publication of JP2011528897A publication Critical patent/JP2011528897A/ja
Publication of JP2011528897A5 publication Critical patent/JP2011528897A5/ja
Application granted granted Critical
Publication of JP5824360B2 publication Critical patent/JP5824360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011519187A 2008-07-25 2009-07-24 新規化合物および方法 Active JP5824360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8369208P 2008-07-25 2008-07-25
US61/083,692 2008-07-25
PCT/EP2009/059586 WO2010010180A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (3)

Publication Number Publication Date
JP2011528897A JP2011528897A (ja) 2011-12-01
JP2011528897A5 true JP2011528897A5 (enExample) 2012-09-06
JP5824360B2 JP5824360B2 (ja) 2015-11-25

Family

ID=41172233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011519187A Active JP5824360B2 (ja) 2008-07-25 2009-07-24 新規化合物および方法

Country Status (24)

Country Link
US (2) US9315556B2 (enExample)
EP (1) EP2315597B1 (enExample)
JP (1) JP5824360B2 (enExample)
KR (2) KR20110060891A (enExample)
CN (2) CN108059660A (enExample)
AU (1) AU2009273133B2 (enExample)
BR (1) BRPI0916705A2 (enExample)
CA (1) CA2731549C (enExample)
CO (1) CO6400198A2 (enExample)
CY (1) CY1119737T1 (enExample)
EA (1) EA022203B1 (enExample)
ES (1) ES2647321T3 (enExample)
HR (1) HRP20171694T1 (enExample)
HU (1) HUE037121T2 (enExample)
IL (1) IL210588A0 (enExample)
LT (1) LT2315597T (enExample)
MX (1) MX2011000981A (enExample)
NO (1) NO2315597T3 (enExample)
PL (1) PL2315597T3 (enExample)
PT (1) PT2315597T (enExample)
SG (1) SG10201505149WA (enExample)
SI (1) SI2315597T1 (enExample)
UA (1) UA107180C2 (enExample)
WO (1) WO2010010180A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2315834T3 (pl) 2008-07-25 2018-12-31 Glaxosmithkline Biologicals S.A. Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN103467582A (zh) * 2012-06-08 2013-12-25 同济大学 结核杆菌重要抗原的高通量筛选及其在结核病诊断中的应用
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
MX2019006728A (es) 2016-12-07 2019-12-02 Glaxosmithkline Biologicals Sa Nuevo proceso.
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
DE112018002827T5 (de) 2017-05-30 2020-04-09 Glaxosmithkline Biologicals S.A. Neue Verfahren zur Herstellung eines Adjuvans
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
US20220218811A1 (en) * 2019-04-17 2022-07-14 Codiak Biosciences, Inc. Methods of treating tuberculosis
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016146A (en) * 1974-12-10 1977-04-05 Biological Developments, Inc. Phenethylamine antigenic conjugates, their preparation, antibodies, and use
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
IL138809A0 (en) 1998-04-07 2001-10-31 Corixa Corp Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
WO2001019993A2 (en) 1999-09-17 2001-03-22 University Of Maryland, Baltimore Virulence genes of m. marinum and m. tuberculosis
JP2003510370A (ja) 1999-10-07 2003-03-18 コリクサ コーポレイション Mycobacteriumtuberculosisの融合タンパク質
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
WO2001098460A2 (en) 2000-06-20 2001-12-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20040121322A9 (en) 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
KR101178776B1 (ko) * 2004-02-06 2012-09-07 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치
SI2426141T1 (sl) 2005-04-29 2015-01-30 Glaxosmithkline Biologicals S.A. Postopek za preprečevanje ali zdravljenje infekcije z M tuberculosis
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CN103550764A (zh) * 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
LT2315773T (lt) 2008-07-25 2016-11-10 Glaxosmithkline Biologicals S.A. Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui
PL2315834T3 (pl) * 2008-07-25 2018-12-31 Glaxosmithkline Biologicals S.A. Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania
DK2421557T3 (en) 2009-04-24 2019-03-25 Statens Seruminstitut TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
AU2011209399B2 (en) 2010-01-27 2014-04-10 Glaxo Group Limited Modified tuberculosis antigens

Similar Documents

Publication Publication Date Title
JP2011528896A5 (enExample)
JP2011528895A5 (enExample)
JP2011528897A5 (enExample)
JP2012126742A5 (enExample)
JP2012136541A5 (enExample)
JP2014051497A5 (enExample)
JP2013231081A5 (enExample)
CA2818990C (en) Designed repeat proteins binding to serum albumin
JP2015518818A5 (enExample)
HRP20161458T1 (hr) Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze
JP2015517488A5 (enExample)
JP2015517489A5 (enExample)
JP2013509429A5 (enExample)
JP2009268467A5 (enExample)
JP2013520405A5 (enExample)
JP2011136997A5 (enExample)
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
JP2010534684A5 (enExample)
NZ702801A (en) Treatment of sanfilippo syndrome type b
JP2008536483A5 (enExample)
JP2012115277A5 (enExample)
JP2011511805A5 (enExample)
JP2012532874A5 (enExample)
JP2013507439A5 (enExample)
NZ608502A (en) Polypeptides that bind to human complement component c5